得力生注射液联合化疗放疗治疗局部晚期非小细胞肺癌疗效分析  

Delisheng Zhusheye combination chemoradiotherapy for locally advanced non-small cell lung cancer

作　　者：任洪波[1] 包中会 李少林[2] 黄碧有[1] 

机构地区：[1]重庆市巴南区第二人民医院肿瘤科 [2]重庆医科大学

出　　处：《临床医药实践》2009年第2Z期1419-1421,共3页Proceeding of Clinical Medicine

摘　　要：目的:观察以得力生注射液联合化疗放疗治疗局部晚期非小细胞肺癌的疗效和毒副作用。方法:2005年1月～2006年12月73例局部晚期非小细胞肺癌患者,随机分为治疗组(得力生注射液联合放化疗)和对照组(放化疗)。治疗组38例,化疗同时加用得力生注射液,给予顺铂(DDP)20mg iv d1～d5,足叶乙甙(Vp-16)100mg ivd1～d5,每21～28天为一周期,得力生注射液30ml静脉滴注14天。放疗结束后继续给予去甲长春花碱(NVB)40mg iv d1、d8,DDP20mg ivd1～d5化疗,得力生注射液30ml静脉滴注14天,共用4个周期。对照组35例放疗方法,化疗方案均与治疗组相同,但未加得力生注射液。结果:治疗组患者有效率78.95%(30/38),稳定率21.05%(8/38),恶化率0%(0/38);对照组有效率65.71%(23/35),稳定率25.71(9/35),恶化率8.57%(3/35).两组比较虽然治疗组有效率,稳定率均高于对照组,但差异无显著性(X2=2.49,P】0.05)。治疗组2年生存率为71.85%、中位生存时间(MST)19个月;对照组2年生存率为51.25%、中位生存时间(MST)14个月;两组比较差异有显著性(X2=5.89,P【0.05)。两组生存曲线比较差异有显著性(X2=6.52,P【0.05)。结论:得力生注射液联合化疗放疗治疗局部晚期非小细胞肺癌的疗效是较高的。Objective:To observe the effect and side effects of Delisheng Zhusheye combination chemoradiotherapy for locally advanced nonsmall cell lung cancer.Methods:Form January 2005 to December 2006,73 patients were randomly allocated into 2 groups.The therapy group(Delisheng Zhusheye combination chemoradiotherapy)ens 38 patients,i.e.firstly with cisplatin 20mg iv d1～5,etoposide 100mg iv d1～5,Delisheng Zhusheye 30ml iv d1～14 repeat every 21～28days.After the radiotherapy continue cisplatin 20mg iv d1～5 and navelbine 40mg iv d1,d8,total 6 cycle.All patients were treated with 60Co external beam radiotherapy 2Gy per day,5 times a week to a total does of 60～70Gy.The radiotherapy area include the primary affection,correspondence mediastinum and the lymph nodes of the clavicle.The spinal cord does less than 40Gy.The antitheses groups(the sequence radiotherapy and chemotherapy)ens35 patients i.e.before the radiotherapy with cisplatin and etoposide.The radiotherapy and the chemotherapy ways and means carried out the same the therapy group.Results:In the Delisheng Zhusheye combination chemora-diotherapy group,the 2-year survival rate were 71.85%,MST 19 months.In the sequence radiotherapy and chemotherapy group,the 2-year survival rate rate were 51.25%.There is significant difference in two groups(P<0.05,x2=5.89)no significant difference in toxicity—side effect.Conclusion:Delisheng Zhusheye combina-tion Chemoradiotherapy for advanced locally advanced non-small cell lung cancer can significantly improve the 2-year survival rate and has little increase in toxicityside effect.

关 键 词：得力生注射液 癌非小细胞肺/放射治疗 癌非小细胞肺/化学治疗 放化疗 预后 疗效 

分 类 号：R734.2[医药卫生—肿瘤]